Ventyx Provides Clinical and Corporate Updates
Ventyx Biosciences, Inc. (VTYX)
Company Research
Source: GlobeNewswire
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx’s R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that the Company added two leading experts to their advisory board and provided an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent pericarditis (“RP”). “We are fortunate to attract such an outstanding group of scientists, clinicians and strate
Show less
Read more
Impact Snapshot
Event Time:
VTYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTYX alerts
High impacting Ventyx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
VTYX
News
- Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Ventyx Biosciences: Why Caution Should Remain [Seeking Alpha]Seeking Alpha
- Ventyx Biosciences (NASDAQ:VTYX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $14.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Ventyx Biosciences (NASDAQ:VTYX) had its price target raised by analysts at Wells Fargo & Company from $11.00 to $14.00. They now have an "overweight" rating on the stock.MarketBeat
VTYX
Earnings
- 11/6/25 - Beat
VTYX
Sec Filings
- 11/26/25 - Form SCHEDULE
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- VTYX's page on the SEC website